Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Reuters

Published November 16, 2026

Helus Pharma's psychedelic depression drug succeeds in late-stage study, shares jump

Read the full story at Reuters

J&J strikes $2.2 billion buyout deal for eye disease biotech Ollin Biosciences. 14 mins ago. China International Import Expo in Shanghai. Site Index.

Surfaced by 5 Google Alerts

  • Psychedelic biotech
  • Magic mushrooms
  • Psychedelic crime
  • Psychedelics asia
  • Gray market psychedelics